诚如招股章程所披露，公司拥有多位台湾创办人，即李瑞河先生及曾明顺先生(台湾创办人)， 及81位台 湾原投资者(81位台湾原投资者)，彼等将于公司将其股份在香港联合交易所有限公司主板上市(上市)的 所得款项注入公司的中国附属公司时须遵守上述两岸投资法规。 智通财经APP讯，天福(03759)发布公告，，内容有关台湾投资者(包括个人及企业)通过其所控制的公司 于中华人民共和国(中国)进行直接或间接投资须经台湾投审会批准。根据两岸投资法规，台湾投资者(包 括个人及企业)通过其所控制的公司于中国进行直接或间接投资须经台湾投审会事先批准。然而，倘所 有台湾投资者于单一中国实体中累计投资总额不超过100万美元时，将允许于向该中国企业作出投资后 六个月内向台湾投审会提交事后备案。根据两岸投资法规，台湾投资者(包括个人及企业)通过其所控制 的公司于中国进行直接或间接投资须经台湾投审会事先批准。然而，倘所有台湾投资者于单一中国实体 中累计投资总额不超过100万美元时，将允许于向该中国企业作出投资后六个月内向台湾投审会提交事 后备案。 于2025年7月1日至2025年12月31日六个月内，公司并无将上市所得款项注入中国附属公司。 ...

智通财经APP讯，康龙化成(03759)发布公告，已达成所有条件并于2026年1月22日完成配售。配售代理 已根据配售协议的条款及条件，按每股配售股份配售价22.82港元，成功向不少于6名独立承配人配售合 共5844.08万股配售股份。 该信息由智通财经网提供 配售的募集资金净额为13.19亿港元，将按以下方式投入使用：约70%将用于公司的项目建设，以加强 公司实验室服务设施、药物工艺开发及生产设施的能力及产能;约10%将用于偿还银行贷款及其他借 款，以优化公司的资本结构;及约20%将用于补充营运资金及作其他一般公司用途。 ...

格隆汇1月22日丨康龙化成(03759.HK)宣布，已达成所有条件并于2026年1月22日完成配售。配售代理已 根据配售协议的条款及条件，按每股配售股份配售价22.82港元，成功向不少于六名独立承配人配售合 共5844.08万股配售股份。 配售的募集资金净额为13.19亿港元，将按以下方式投入使用：(a)约70%将用于公司的项目建设，以加 强本公司实验室服务设施、药物工艺开发及生产设施的能力及产能；(b)约10%将用于偿还银行贷款及其 他借款，以优化公司的资本结构；及(c)约20%将用于补充营运资金及作其他一般公司用途。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03759 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司法 權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內或 在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券根據 《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證券 法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國登記 本公告所述任何證券或在美國公開發售任何證券。 配售的募集資金淨額為1,318.7百萬港元，將按以下方式投入使用： Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 ...

在最近有统计数据的5个交易日内，钧达股份（02865）、中庆股份（01855）、康龙化成（03759）港股 通持股占比增加值最大，分别增加13.48%、6.42%、4.45%；华夏恆生科技（03088）、南京熊猫电子股 份（00553）、旭辉控股集团（00884）港股通持股占比减少值最大，分别减 少-14.18%、-4.58%、-4.31%。 具体数据如下（交易所数据根据T+2日结算）： 智通财经APP获悉，根据2026年1月21日披露数据，三花智控（02050）、狮腾控股（02562）、中远海 能（01138）港股通持股占比增加值最大，分别增加2.19%、1.89%、1.47%；优必选（09880）、迈富时 （02556）、微盟集团（02013）港股通持股占比减少值最大，分别减少-0.85%、-0.70%、-0.68%。 4、港股通5日占减持榜（前10名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 华夏恆生科技(03088) | -14.18% | 6.09% | | 南京熊猫电子股份(00553) | -4.58% | 45.48% | | 旭辉控股集 ...

| 股票名称 | 沽空金额↓ | 沽空比率 | 偏离值 | | --- | --- | --- | --- | | 泡泡玛特(09992) | 10.08 亿元 | 17.14% | -7.69% | | 小米集团-W(01810) | 8.25 亿元 | 10.26% | -11.52% | | 美团-W(03690) | 7.77 亿元 | 17.49% | 1.85% | | 中国人寿(02628) | 7.18 亿元 | 23.90% | 3.47% | | 洛阳钼业(03993) | 6.87 亿元 | 35.31% | 21.99% | | 百度集团-SW(09888) | 6.24 亿元 | 21.01% | -5.12% | | 阿里巴巴-W(09988) | 6.13 亿元 | 6.91% | -7.34% | | 比亚迪股份(01211) | 4.97 亿元 | 20.25% | 0.39% | | 腾讯控股(00700) | 4.79 亿元 | 3.27% | -7.53% | | 中国平安(02318) | 3.47 亿元 | 16.40% | -12.96% | 前十大沽空偏离值排行 ...

Group 1 - The core viewpoint of the articles indicates a mixed performance in the medical and healthcare sector, with the China Medical and Medical Device Innovation Index experiencing a decline of 0.85% as of January 20, 2026, while certain stocks like Xinhecheng and Xingqi Eye Medicine showed gains [1] - The medical innovation ETF saw a decrease of 0.80%, with the latest price at 0.37 yuan, reflecting the overall market sentiment [1] - The brain-computer interface concept is gaining traction, supported by a significant investment of over 730 billion yuan in technology loans by the China Export-Import Bank, focusing on AI, brain-computer interfaces, humanoid robots, and high-end instruments [1] Group 2 - According to J.P. Morgan's conference, over 20 Chinese companies participated, highlighting the growing global interest in domestic innovative drugs and medical devices, which is expected to boost industry sentiment [1] - The China Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2] - Recent data shows a net inflow of 1.8727 million yuan into the medical innovation ETF, with a total of 59.7643 million yuan over the past five trading days, indicating a positive trend in investor interest [2]

Core Insights - The data reveals significant changes in the stock holdings of various companies under the Hong Kong Stock Connect program, with notable increases and decreases in ownership percentages. Group 1: Increased Holdings - Zhongqing Holdings (01855) saw the largest increase in stock holdings, rising by 3.01% to a total holding of 13.35% [2] - Kanglong Chemical (03759) experienced a 2.91% increase, bringing its holding to 56.33% [2] - Haotian International Investment (01341) increased by 2.35%, with a current holding of 62.91% [2] - Other notable increases include Juxing Legend (06683) at +1.68% (19.00%), and Zhongwei New Materials (02579) at +1.41% (13.14%) [2] Group 2: Decreased Holdings - Goldwind Technology (02208) had the largest decrease, down by 2.28% to a holding of 47.98% [3] - China Cosco Shipping Energy Transportation (01138) decreased by 1.61%, now holding 59.13% [3] - Shandong Molong Petroleum Machinery (00568) saw a reduction of 1.59%, with a current holding of 57.08% [3] - Other significant decreases include Junda Co., Ltd. (02865) at -1.04% (48.24%) and Nanjing Panda Electronics (00553) at -0.93% (45.78%) [3] Group 3: Five-Day Changes - Junda Co., Ltd. (02865) had the highest five-day increase in holdings, up by 19.19% to 48.24% [4] - Zhongqing Holdings (01855) increased by 5.23%, reaching 13.35% [4] - Baidu's subsidiary, Baidu Apollo (02315), saw a 4.45% increase, with a holding of 19.50% [4] - Other notable increases include Zhaoyan Pharmaceutical (06127) at +4.08% (63.10%) and Weimob Group (02013) at +3.96% (30.41%) [4] Group 4: Five-Day Decreases - Huaxia Hengsheng Technology (03088) experienced the largest five-day decrease, down by 14.16% to 6.06% [4] - GF Securities (01776) decreased by 6.64%, now holding 53.59% [4] - Goldwind Technology (02208) saw a reduction of 5.22%, with a current holding of 47.98% [4] - Other significant decreases include Nanjing Panda Electronics (00553) at -4.80% (45.78%) and Chifeng Gold (06693) at -3.53% (40.57%) [4] Group 5: Twenty-Day Changes - Junda Co., Ltd. (02865) had a notable increase of 16.48%, reaching a holding of 48.24% [5] - Zhongwei New Materials (02579) increased by 10.89% to 13.14% [5] - Lion Holdings (02562) saw a rise of 9.50%, with a holding of 51.61% [5] - Other significant increases include Junsheng Electronics (00699) at +7.77% (16.56%) and Shandong Molong (00568) at +6.69% (57.08%) [5] Group 6: Twenty-Day Decreases - Huaxia Hengsheng Technology (03088) had the largest decrease of 14.15%, now holding 6.06% [5] - China Metallurgical Group (01618) decreased by 6.38%, with a holding of 35.53% [5] - GF Securities (01776) saw a reduction of 5.56%, now at 53.59% [5] - Other notable decreases include Beijing Mechanical and Electrical Holdings (00187) at -4.73% (44.59%) and China Cosco Shipping Energy Transportation (01138) at -4.66% (59.13%) [5]

Core Viewpoint - The Hong Kong capital market has seen a significant increase in refinancing activities at the beginning of 2026, with over HKD 27 billion raised, marking a more than 20-fold increase compared to the same period in 2025, setting a vibrant tone for the year ahead [1][3]. Group 1: Active Refinancing at the Start of 2026 - As of January 18, 2026, Hong Kong-listed companies have raised over HKD 27 billion through various methods such as placements and rights issues, compared to HKD 1.1 billion in the same period of 2025 [1][3]. - The robust refinancing activity is built on the historical high of HKD 325.32 billion in 2025, which surpassed the IPO fundraising scale for the first time [3]. - Major companies like BYD and Xiaomi have completed significant fundraising projects, contributing to a trend of continuous capital replenishment [3]. Group 2: Structural Characteristics of Refinancing - The refinancing activities in early 2026 are characterized by a diverse industry distribution, including sectors like oil and gas, construction, software services, and healthcare [7]. - Notable companies such as SF Express and Jitu Express have raised over HKD 1 billion, indicating a clear differentiation in fundraising scales [7]. - The use of raised funds is closely aligned with core business strategies, including international expansion, technology R&D, and financial structure optimization [7]. Group 3: Advantages of Hong Kong's Refinancing Market - The efficiency of Hong Kong's refinancing system allows companies to quickly seize market opportunities without prior regulatory approval for placements [4]. - The flexible and diverse financing tools available in the Hong Kong market cater to various corporate needs, enhancing the ability to raise funds [5]. - The market's recovery and valuation improvements since Q3 2024 have created a favorable environment for refinancing activities [5]. Group 4: Emerging Trends in Refinancing - The refinancing landscape is evolving, with a notable increase in strategic mutual holdings among companies, exemplified by the collaboration between SF Express and Jitu Express [8]. - The current refinancing structure shows a higher proportion of traditional and consumer industries compared to emerging sectors, highlighting the complementary nature of Hong Kong and A-share markets [8]. - Future trends indicate that refinancing will remain high but with a more stable growth rate, and the focus will shift towards optimizing capital structures and enhancing R&D capabilities [10].